Women with BRCA1/2 and choices for breast/ovarian cancer prevention
Research type
Research Study
Full title
Preferences of Women With Inherited Mutations in the Breast and Ovarian Cancer Susceptibility Genes (BRCA1 or BRCA2) for Treatments to Prevent Breast Cancer: A Discrete Choice Experiment
IRAS ID
168712
Contact name
Gareth Evans
Contact email
Sponsor organisation
Amgen Inc
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
A survey using discrete choice experiment methodology will be used to assess how the attributes of women with BRCA1/2 mutations are associated with the choices of surgical (mastectomy, oophorectomy) and drug treatments (chemoprevention) for the prevention of breast and ovarian cancer. The study will be conducted according to best practice guidelines published by the International Society of Pharmacoeconomics and Outcomes Research. Eligible women will be mailed an invitation letter explaining the rationale of the study and a given a website where they can take the survey if they give consent and agree to participate.
REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
15/NW/0672
Date of REC Opinion
28 Oct 2015
REC opinion
Further Information Favourable Opinion